Moloney Securities Asset Management’s Unity Biotechnology UBX Stock Holding History

Moloney Securities Asset Management’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,100	Closed	-$16K	–	458
2021 Q4	$16K	Sell	1,100 -1,000	-48%	-$21.9K	﹤0.01%	432
2021 Q3	$63K	Buy	+2,100	New	+$74.1K	0.01%	420
2021 Q1	–	Sell	-4,195	Closed	-$220K	–	437
2020 Q4	$220K	Sell	4,195 -350	-8%	-$16.9K	0.05%	339
2020 Q3	$157K	Buy	4,545 +2,400	+112%	+$152K	0.04%	305
2020 Q2	$186K	Sell	2,145 -3,050	-59%	-$226K	0.05%	279
2020 Q1	$301K	Sell	5,195 -3,150	-38%	-$199K	0.11%	188
2019 Q4	$602K	Buy	8,345 +7,345	+735%	+$518K	0.19%	145
2019 Q3	$61K	Sell	1,000 -700	-41%	-$49.5K	0.02%	319
2019 Q2	$162K	Buy	+1,700	New	+$145K	0.05%	295

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Moloney Securities Asset Management's UBX Position: Q1 2022 in Review

Moloney Securities Asset Management sold out of Unity Biotechnology (UBX) in Q1 2022, closing a stake of 1,100 shares — an estimated $16K sold.

Moloney Securities Asset Management first reported a position in UBX in Q2 2019 and held it in 9 quarters. The position peaked at $602K in Q4 2019. 70 funds tracked by Wall St. Rank hold UBX as of Q1 2022.

Moloney Securities Asset Management reported no remaining Unity Biotechnology position as of Q1 2022 after selling out during the quarter.
Moloney Securities Asset Management sold 1,100 Unity Biotechnology shares in Q1 2022, an estimated $16K.
Moloney Securities Asset Management first reported a position in Unity Biotechnology in Q2 2019 and held it in 9 quarters.
Moloney Securities Asset Management's Unity Biotechnology position peaked at $602K in Q4 2019.
70 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2022.

Based on Moloney Securities Asset Management's 13F filing for Q1 2022, filed 10 May 2022.